Ashland(ASH) - 2026 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Sales for the quarter were $386 million, down 5% year-over-year, with the Avoca divestiture accounting for approximately $10 million or about 2% of the decline [10] - Adjusted EBITDA was $58 million, down 5% year-over-year, including a $1 million impact from the Avoca divestiture [11] - Adjusted EPS, excluding intangible amortization, was $0.26, down 7% from the prior year [12] Business Line Data and Key Metrics Changes - Life Sciences sales were $139 million, up 4% from the prior year, driven by resilient pharma demand and strength in high-value cellulosic excipients [14] - Personal Care sales were $123 million, down 8% year-over-year, primarily due to the Evoca divestiture, with organic sales declining 1% [18] - Specialty Additives sales were $102 million, down 11% year-over-year, with coatings and construction driving the decline [23] Market Data and Key Metrics Changes - Coatings demand was particularly weak in China and select export markets, while construction softness reflected broader market conditions [5] - Life Sciences continued to grow, supported by steady demand and ongoing innovation momentum [10] - Specialty Additives faced muted demand, particularly in coatings and construction [5] Company Strategy and Development Direction - The company is focused on executing its strategic priorities, including innovation and globalized initiatives, to drive growth and improve margins [4] - The total cost savings target of approximately $30 million for fiscal 2026 remains on track, with ongoing efforts in network optimization and productivity improvements [25] - The company aims to deliver structural cost improvements and enhance systems and processes to strengthen performance [26] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing demand softness in coatings and construction but expressed optimism about improving momentum in Life Sciences and Personal Care [4] - The outlook for fiscal 2026 has been narrowed to an adjusted EBITDA range of $400 million to $420 million, reflecting a prudent view of market conditions [28] - Temporary impacts from operational challenges, including delays in the Calvert City unit startup and weather-related disruptions, are expected to affect the second quarter [30] Other Important Information - The company reported strong cash generation with $125 million from operating activities and $26 million of ongoing free cash flow [12] - Total liquidity at the end of the quarter was approximately $900 million, with net debt at $1.1 billion and net leverage at 2.7x [12] Q&A Session Summary Question: Can you talk about the customer outage impacting demand in Personal Care? - Management confirmed that the outages were on the customer side and not related to supply issues from the company. Most outages have been resolved, and recovery is expected in Q2 [43][44] Question: Should we see volumes start to turn the corner in Personal Care? - Management indicated that with the Evoca divestiture now lapped, they expect to see positive volume growth as the year progresses, with most customers indicating flat to low single-digit growth [48] Question: On the China coatings demand, is there a line of sight to the bottom? - Management noted that while the market has been challenging, they expect to see easing in the second half of the year, with efforts focused on commercial discipline, productivity, and innovation [61][62]